Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum

SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ — Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.